Your browser is no longer supported. Please, upgrade your browser.
Galectin Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own14.20% Shs Outstand57.05M Perf Week-1.36%
Market Cap126.72M Forward P/E- EPS next Y-0.68 Insider Trans-0.78% Shs Float40.51M Perf Month-16.15%
Income-20.90M PEG- EPS next Q-0.16 Inst Own17.40% Short Float11.77% Perf Quarter-21.86%
Sales- P/S- EPS this Y-1.20% Inst Trans-0.08% Short Ratio22.26 Perf Half Y-25.09%
Book/sh0.51 P/B4.27 EPS next Y-58.10% ROA-49.70% Target Price- Perf Year-27.33%
Cash/sh0.56 P/C3.89 EPS next 5Y- ROE-56.50% 52W Range1.50 - 3.85 Perf YTD-2.68%
Dividend- P/FCF- EPS past 5Y13.00% ROI- 52W High-43.38% Beta2.01
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low45.33% ATR0.14
Employees7 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)36.07 Volatility4.95% 6.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-109.70% Profit Margin- Rel Volume1.25 Prev Close2.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume214.33K Price2.18
Recom2.00 SMA20-5.89% SMA50-13.29% SMA200-17.11% Volume267,782 Change-0.46%
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
Jan-19-21 11:15AM  
Dec-11-20 08:00AM  
Dec-04-20 04:17PM  
Dec-01-20 08:00AM  
Nov-09-20 08:00AM  
Nov-02-20 08:02AM  
Oct-12-20 08:11AM  
Oct-06-20 03:30PM  
Sep-29-20 12:00PM  
Sep-22-20 08:04AM  
Sep-10-20 08:00AM  
Sep-09-20 11:46AM  
Sep-02-20 08:00AM  
Aug-10-20 08:00AM  
Aug-03-20 12:48PM  
Jun-30-20 09:05AM  
Jun-04-20 09:48PM  
May-22-20 08:17AM  
May-11-20 08:00AM  
May-04-20 08:37AM  
Apr-30-20 09:00AM  
Apr-02-20 08:04AM  
Mar-16-20 08:00AM  
Feb-20-20 08:00AM  
Feb-05-20 04:11PM  
Feb-04-20 08:04AM  
Dec-20-19 06:38PM  
Dec-09-19 08:00AM  
Dec-05-19 12:06PM  
Nov-26-19 08:00AM  
Nov-18-19 04:10PM  
Nov-12-19 08:00AM  
Nov-11-19 09:47AM  
Nov-05-19 08:00AM  
Oct-28-19 08:39AM  
Sep-17-19 08:00AM  
Sep-11-19 10:13AM  
Aug-27-19 03:21PM  
Aug-09-19 08:00AM  
Aug-07-19 11:20AM  
Aug-06-19 10:51AM  
Aug-05-19 08:05AM  
May-28-19 09:05AM  
May-27-19 08:44AM  
May-23-19 05:30PM  
May-10-19 08:05AM  
Apr-15-19 08:00AM  
Apr-02-19 08:00AM  
Mar-22-19 10:19AM  
Mar-06-19 11:34AM  
Feb-26-19 07:25AM  
Feb-25-19 08:00AM  
Feb-13-19 03:36PM  
Feb-04-19 09:27AM  
Feb-01-19 10:07AM  
Jan-30-19 09:30AM  
Jan-15-19 08:00AM  
Dec-25-18 01:28PM  
Dec-20-18 08:30AM  
Nov-27-18 08:15AM  
Nov-19-18 09:19AM  
Nov-13-18 08:00AM  
Nov-05-18 08:37AM  
Oct-15-18 10:22AM  
Oct-11-18 07:30AM  
Sep-26-18 03:21PM  
Sep-21-18 10:43AM  
Sep-20-18 08:25AM  
Sep-18-18 08:53AM  
Aug-31-18 02:46PM  
Aug-21-18 11:27AM  
Aug-20-18 08:42AM  
Aug-14-18 08:00AM  
Aug-03-18 07:30AM  
Jul-26-18 08:57AM  
Jul-11-18 07:45AM  
Jun-27-18 12:56PM  
Jun-26-18 08:55AM  
Jun-22-18 10:40AM  
Jun-17-18 04:17PM  
Jun-16-18 07:18AM  
Jun-15-18 08:07AM  
Jun-14-18 09:23AM  
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. The company was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AMELIO GILBERT FDirectorJan 11Sale2.1760,000130,20060,614Jan 19 09:00 AM
10X Fund, L.P.10% OwnerJan 04Sale2.2310,00022,3006,346,440Jan 05 05:36 PM
10X Fund, L.P.10% OwnerOct 13Sale2.9710,00029,7006,356,440Oct 15 05:03 PM
Uihlein Richard EDirectorSep 04Buy2.5510,00025,5007,893,191Sep 09 08:00 AM
FREEMAN KEVIN DDirectorSep 04Buy2.575,00012,84825,000Sep 09 08:00 AM
FREEMAN KEVIN DDirectorMar 19Buy1.646,0009,84420,000Mar 20 08:30 AM
Uihlein Richard EDirectorFeb 13Option Exercise3.0565,513200,0037,883,191Feb 14 08:01 AM
LEWIS JOELDirectorFeb 09Option Exercise2.398,00019,120107,104Feb 10 04:31 PM